Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04356690 · ClinicalTrials.gov registry record · Phase 2
Etoposide in Patients With COVID-19 Infection
A Phase 2 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04356690 is a Phase 2 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT04356690, a Phase 2 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a randomized, open-label phase II study designed to evaluate the safety and efficacy of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection. Randomization will be performed with a 3:1 allocation ratio. Treatment will be comprised of etoposide administered intravenously at a dose of 150 mg/m2 on Days 1 and 4 in patients with COVID-19 infection meeting eligibility criteria. Subsequent doses of etoposide will be allowed if the investigator and treating physician believe the patient had clinical benefit from etoposide therapy but subsequently has evidence of recurrent clinical deterioration. Subjects randomized to control will receive standard of care treatment. No placebo will be used.
Interventions
- DRUG Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-05-08 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04356690
The ClinicalTrials.gov registry entry for NCT04356690 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etoposide is the first listed.
NCT04356690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04356690 about?
NCT04356690 is a clinical study titled "Etoposide in Patients With COVID-19 Infection". This is a randomized, open-label phase II study designed to evaluate the safety and efficacy of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection. Randomization will be performed with a 3:1 allocation ratio. Treatment will be comprised of etoposide administered intravenously...
What is the current status of trial NCT04356690?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-05-08. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT04356690?
The interventions under investigation include: Etoposide (DRUG).
Who is sponsoring clinical trial NCT04356690?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.